Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NEW ZEALAND STOCK EXCHANGE  >  A2 Milk Company Ltd    ATM   NZATME0002S8


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

A2 Milk : Growth And Challenges Ahead For a2 Milk

share with twitter share with LinkedIn share with facebook
share via e-mail
11/19/2019 | 09:59pm EST

A2 Milk envisages strong growth in the year ahead despite the challenges in the Chinese infant formula market. The main issue for brokers is whether the necessary investment will deliver the expected returns.

-Marketing, investment and costs likely weighted to the second half
-Strong growth expected despite challenging trading conditions
-Re-negotiated supply contract with Synlait Milk highlights improved pricing


Broker opinions differ widely on the near-term outlook for a2 Milk ((A2M)) as the company negotiates complex changes in the Chinese infant formula market and advances its marketing of liquid milk in the US.

Ord Minnett assesses the step-up in investment that is required to access the significant opportunity in the Chinese infant formula and US liquid milk market is now more likely to occur from 2020 onwards.

There are also ongoing challenges in the channel mix and rising competition in the Chinese market for infant formula. Breaking even in the US liquid milk category is also expected to be long-dated. As the stock offers limited valuation support, the broker retains a Lighten rating.

The company recognises further growth in the Chinese market requires success in cross-border e-commerce and mother & baby stores, along with other bricks & mortar channels. Yet Ord Minnett points out the abandonment of the US break-even target to better pursue the opportunity has resulted in margin compression being deferred to 2020, rather than being avoided.

Morgans agrees the margin will still decline relative to FY19 as the company moves into an investment phase. Revenue growth will now come at a much higher cost than in the past given a2 Milk is not as reliant on daigou (product purchased outside China for sale in China).

Still, the broker considers the forecast for strong growth a credible outcome, in the light of peer results that highlight the challenging trading conditions, increased competition and regulatory changes. Declining birth rates in China are also cited as a limiting factor going forward, although the company argues that increased household penetration still contributes to the attractive category growth prospects.


FY20 margin guidance has been upgraded to 29-30% while the company has guided to a first half margin of 31-32%. The reason for this is that marketing, investment and costs are likely to be weighted to the second half.

The fact that gross margin drove the upgrade to the overall outlook is positive, UBS suggests, as it indicates a2 Milk is not discounting its product in order to create more volume, amid some concerns about inventory levels. UBS has become incrementally more positive after channel checks regarding inventory levels.

The main issue the company faces is about what is a realistic long-term share of the Chinese infant formula market and what level of profitability can be achieved. UBS forecasts long-term share of 11% and group operating earnings margins of 30%. This should mean this business delivers around 16% five-year compound growth.

Citi reiterates a Sell case, although acknowledges momentum appears strong. The broker believes margin expectations from FY21 do not reflect the impact of increased investment and are too optimistic. Competition is also heightened, as multiple operators enter the segment, although this will take time to play out as switching is not significant at present.

Morgan Stanley agrees, assessing the majority of the margin upgrade can be attributed to price/channel mix benefits and an earlier forecast that was conservative. Management has indicated that store velocity drove the majority of growth in China in the first half to date. Moreover, the broker suggests infant formula sales data, while imperfect, signals softer end-market pricing, which implies demand is slowing.

CLSA, not one of the seven stockbrokers monitored daily on the FNArena database, downgrades to Sell from Underperform. The broker implies, from the update, that the second half operating earnings margin will fall to around 28%. The issue is whether this is a reliable gauge for FY21 margins. While some recovery is expected it is not enough to turn CLSA bullish and a target of $12.80 is in place.

Bell Potter, also not one of the seven, sticks with a Hold rating and $13.55 target, noting, for the first time, the company has not released a four-month trading result but instead provided an update to guidance. First half guidance implies infant formula revenue growth in Australia is stronger than Bell Potter previously expected while China and US revenues are softer.

Wilsons, not one of the seven, takes a different view and upgrades to Overweight, believing the current share price represents an attractive entry point, retaining a target of $15.30. The broker is encouraged by the trading update, coming 10 months after the launch of China's new e-commerce law, as it demonstrates a smooth transition from the daigou-led market to a more direct sales model.

Wilsons had been uncertain about this aspect, as well as regarding returns from increased marketing expenditure, but now believes the renegotiated supply contract with Synlait Milk ((SM1)) provides a buffer. A2 milk has extended its contract to five years, with the main impact being improved pricing from FY21 and Macquarie expects this will drive gross margin expansion.

There was no reference to the 12% marketing-to-sales ratio which could otherwise be used to anchor revenue. Still, Macquarie assesses the size of price increases taken in FY20 reflect confidence in the outlook for demand.

FNArena's database has two Buy ratings, two Hold and three Sell. The consensus target is $13.28, suggesting -3.5% downside to the last share price. Targets range from $10.80 (Morgan Stanley) to $16.20 (Macquarie).

FNArena is proud about its track record and past achievements: Ten Years On

All material published by FN Arena is the copyright of the publisher, unless otherwise stated. Reproduction in whole or in part is not permitted without written permission of the publisher.

© 2019 Acquisdata Pty Ltd., source FN Arena

Stocks mentioned in the article
ChangeLast1st jan.
A2 MILK COMPANY LTD End-of-day quote.
SYNLAIT MILK LTD End-of-day quote.
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on A2 MILK COMPANY LTD
2019A2 MILK : New Zealand's a2 Milk Reaffirms Guidance, Strategy After CEO Quits
2019A2 MILK : CEO of New Zealand's a2 Milk Resigns, Interim Chief Named
2019DAVID HEARN : Safestore Holdings Appoints David Hearn as Chairman From January
2019A2 MILK : Market Expected to Attain an Estimated Value of USD 18.1 billion by 20..
2019A2 MILK : Change in substantial holding
2019A2 MILK : Growth And Challenges Ahead For a2 Milk
2019Australian shares extend falls; weak China data weighs on market
2019Caution Required For Formula And Supplements
2019A2 MILK : Ord Minnett rates A2M as Lighten
2019Diversity Paramount For Synlait Milk
More news
Financials (NZD)
Sales 2020 1 665 M
EBIT 2020 488 M
Net income 2020 344 M
Finance 2020 790 M
Yield 2020 -
P/E ratio 2020 33,1x
P/E ratio 2021 26,9x
EV / Sales2020 6,27x
EV / Sales2021 5,03x
Capitalization 11 222 M
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 15,39  NZD
Last Close Price 15,25  NZD
Spread / Highest target 14,8%
Spread / Average Target 0,93%
Spread / Lowest Target -24,6%
EPS Revisions
Geoffrey Howard Babidge Chief Executive Officer
David Lovat Hearn Chairman
Shareef Khan Chief Operations Officer
Strauss Race Chief Financial Officer
Julia Cecile Hoare Deputy Chairman